FDA Grants IND Clearance to CAR T-cell Drug ICTCAR014 for R/R Non-Hodgkin Lymphoma

An Investigational New Drug application for chimeric antigen receptor-T cell agent, ICTCAR014, has been cleared by the FDA for treatment of patients with relapsed/refractory non-Hodgkin lymphoma, including those with PD-L1-positive tumors, according to a press release from Innovative Cellular Therapeutics.

Read the full article here

Related Articles